Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE-031 (Ramatercept): Myostatin Inhibition for Muscle Growth - Exploring Peptides

Muscle growth in the human body is tightly controlled by biological signals that prevent excessive tissue development. One of the most important regulators of this process is myostatin, a protein that acts as a natural limit on muscle size. Because of its role

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Muscle growth in the human body is tightly controlled by biological signals that prevent excessive tissue development. One of the most important regulators of this process is myostatin, a protein that acts as a natural limit on muscle size. Because of its role in restricting muscle growth, researchers have long investigated ways to temporarily block or modulate myostatin activity as a potential strategy for treating muscle-wasting conditions.

This research led to the development of compounds designed to interfere with the signaling pathways that regulate muscle mass. Among them is ACE-031, also known as Ramatercept, an investigational fusion protein created to bind proteins involved in the myostatin signaling pathway and alter how the body regulates muscle development.

Key Takeaways

ACE-031 (Ramatercept) is an investigational fusion protein designed to inhibit myostatin, a protein that normally limits muscle growth.

It works by mimicking the activin type IIB receptor (ActRIIB), binding to myostatin and related proteins so they cannot signal muscle cells to restrict growth.

Blocking myostatin may increase muscle mass, strength, and muscle fiber size, which is why ACE-031 has been studied for conditions like Duchenne muscular dystrophy.

Early clinical studies showed increases in lean body mass and muscle volume, though some trials were stopped due to side effects such as nosebleeds and vascular changes.

What is ACE-031 or Ramatercept

Mechanism of Action

ACE-031 and Muscle Growth

Myostatin and Its Impact on Muscle Health

In these conditions, muscles struggle to repair and regenerate, leading to progressive weakness. Myostatin inhibitory peptides, could counteract this effect, offering a way to restore muscle function.

The Science Behind Myostatin Inhibitory Peptides

Research and Clinical Studies on ACE-031

Determined Safety Profile and Potential Side Effects

Potential Benefits of Ace-031

ACE-031 offers a range of promising benefits for muscle development and overall health, particularly for those facing muscle-wasting conditions. This compound blocks myostatin, a protein that naturally limits muscle growth, allowing muscle tissue to develop more than usual. Muscle strength can improve as a result, helping patients with neuromuscular diseases regain and maintain their ability to perform everyday tasks.

Stronger muscles can improve respiratory function in muscular dystrophies that affect breathing muscles, bringing relief and better overall health. Increased muscle strength also helps reduce the risk of osteoporosis by maintaining bone density, which is especially important for those who are less active. Muscles play an important role in how the body uses energy, so keeping them strong can support a healthier metabolism.

Final Word

ACE-031 stands out as a unique approach to addressing muscle weakness and degeneration. Designed to inhibit myostatin, this peptide shows potential in treating conditions like Duchenne muscular dystrophy and age-related muscle loss. Research also points to its promise in supporting recovery from injury and enhancing physical performance in sports.

While studies so far reveal encouraging data, ACE-031 remains in the early stages of exploration. As new trials and data emerge, this peptide continues to hold promise as a breakthrough treatment for improving muscle strength, restoring function, and elevating quality of life for those facing muscle-related challenges.

Sourcing

USA

LIMITLESS LIFE NOOTROPICS aka Biotech

Use Discount Code: EP20

SCANTIFIX

Use Discount Code: Exploringpeptides

Canada

BIOSLAB

Use Discount Code: EP10

Europe

DNLABResearch

Use Discount Code: EP15

Australia

LVLUPHEALTH

References

[1] Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21. PMID: 23169607.

[2] Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23. PMID: 27462804.

[3] Jang J, Park S, Kim Y, Jung J, Lee J, Chang Y, Lee SP, Park BC, Wolfe RR, Choi CS, Kim IY. Myostatin Inhibition-Induced Increase in Muscle Mass and Strength Was Amplified by Resistance Exercise Training, and Dietary Essential Amino Acids Improved Muscle Quality in Mice. Nutrients. 2021 Apr 29;13(5):1508. doi: 10.3390/nu13051508. PMID: 33947024; PMCID: PMC8146053.

[4] Buehring B, Binkley N. Myostatin--the holy grail for muscle, bone, and fat? Curr Osteoporos Rep. 2013 Dec;11(4):407-14. doi: 10.1007/s11914-013-0160-5. PMID: 24072591.

Table of content

Related articles

SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

Adalank vs Selank: Differences, Benefits and Effects

Adamax vs Semax: Comparison, Benefits, and Effects

Common Mistakes When Reconstituting Peptides

Peptides Vs Proteins: What’s The Difference?

What Are Peptides and How Do They Work?

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Myostatin and Cardiomyocyte Hypertrophy: Physiological vs Pathological Contexts

The distinction between physiological and pathological cardiac hypertrophy is mechanistically critical for interpreting ACE-031’s cardiac biology. Physiological hypertrophy (exercise-induce…

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

Can I use ACE-031 as a research chemical if I can find it?

ACE-031 has never been approved for human use and clinical development was discontinued. Any product sold as ACE-031 is of unknown origin and quality. The compound is a complex fusion protein sensitive to degradation, making DIY sourcing extremely risky with high contamination likelihood.

Source: peptide-db.com ↗

ACE-031 and Muscular Dystrophy Research: Myostatin Inhibition and Muscle Mass Biology (UK 2026)

ACE-031 is a fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to an IgG1 Fc region. It acts as a ligand trap, sequestering myostatin and related TGF-β superfamily ligands (activin A, GDF-11) and preventing them from binding to endogenous ActRIIB receptors on muscle cells. The resulting disinhibition of muscle protein synthesis produces profound increases in muscle mass and strength in preclinical models. ACE-031 was developed by Acceleron Pharma specifically as a potential treatment for muscle-wasting diseases, including Duchenne muscular dystrophy (DMD). 🔗 Related Reading: For a comprehensive overview of ACE-031 research, mechanisms, UK sourcing, and safety data, see our ACE-031 UK Complete Research Guide.

Source: peptideslabuk.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

ACE-031 Dosage, Reconstitution & Mixing Trends

See ACE-031 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. ACE-031 (ramatercept) is a soluble activin receptor type IIB-Fc fusion protein engineered to act as a myostatin trap, sequestering myostatin and related TGF-beta family ligands to permit muscle hypertrophy. Acceleron Pharma advanced it into Phase 2 trials in Duchenne muscular dystrophy that were halted on safety grounds. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with ACE-031. 7 ACE-031 reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (3 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (5 sessions). The most common dosing frequency is once weekly (1 logged protocols). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Source: worldpeptideassociation.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →